
CancerVision
Turning DNA data
into action with
whole genome insights
INOCRAS

SEE YOUR CANCER FROM NEW ANGLES

Get the answers you need with our extensive genetic testing

It can be frustrating to explore uncertainties on your own. When it comes to your health or that of your loved ones, you may want to explore all possible options.

CancerVision, our whole genome diagnostic testing for cancer profiling, is designed to help uncover critical information other tests could have missed.

For the same patient

Whole Genome





Conventional cancer panel tests



Whole Genome Sequencing
>99% genome-wide coverage

We look at the whole picture of your genomic blueprint, not just a small part of it. This allows us to find not only simple changes to your DNA, but complicated ones too. When we see more, we get more insights.

Targeted Panel Sequencing
<0.1% genome-wide sequencing

Looking at a much smaller portion of your genetic blueprint could mean missing key changes to your DNA, which could contribute to less precise treatment strategies.

CancerVision

Take control of your health

Get the whole picture of your genetic health and more insights about your cancer, all within two weeks.**

- **Whole genome sequencing** that looks at your genes for a comprehensive genetic view of your cancer
- **Insights to support your doctor's treatment decisions** and personalized therapy selections based on your test findings
- **Personalized support from a genetic counselor** to answer your questions and help you discuss your next steps in care
- **Clinical trial matching** support based off your unique biomarkers and your other medical information

Price: $4,000†

** 2 week turnaround time is from receipt of your tissue and blood samples at our lab. †The listed price is a general estimate. The price may vary depending on your country and the specific scope of services we provide tailored to your need

DID YOU KNOW

More than 25% of cancer patients have disease-causing changes in their DNA that are often missed by conventional cancer tests.* Whole genome sequencing takes an extensive look at your genes to give you a more complete view of your health for a healthier future.

*Nature 578, 82–93 (2020)

STORIES WITH IMPACT

Sarah's story

Diagnosed with pancreatic cancer at age 40, Sarah had previously been successfully treated for breast cancer at 20. Several genetic tests, including a tissue panel test and hereditary cancer panel test, failed to reveal the root cause of her disease and why she got two different types of cancer at different points in her life.

The CancerVision test provided a potential breakthrough. We discovered Sarah had a genetic mutation in a gene called BRCA1. This mutation was present from Sarah's birth and contributed to her breast cancer by impairing her body's ability to repair DNA damages that could lead to other cancers.

The CancerVision findings identified more informed treatment options for Sarah and gave her a clearer picture of what was driving her cancer at a genetic level.

Request an order for Cancer**Vision**

testing today at **inocras.com**

While all patient names provided are fictionalized to ensure privacy and confidentiality, the age, disease information, and diagnostic process in the testimonials are based on real cases. Please note that clinical outcomes may vary for each individual. These patient stories are based on collaborative research funded by Inocras.

How can I order Cancer**Vision**?

Sign up

Fill out the online request form and consent form at **inocras.com**.

Clinician approval

An external clinician will review and order your test.

Blood sample collection

Once your test order is made, we'll send you a link to make an appointment with a phlebotomist to visit your home and draw your blood.

Tumor tissue sample collection

We will work with your care team/pathologist's office to collect a tumor tissue sample – no action is required from you.

Genetic counselor appointment

When your report is ready, you will receive a notification with a link to make an appointment with a genetic counselor who will review your results with you.

Result review

A genetic counselor will review your Cancer**Vision** report and optional clinical trial matching report with you.

Scan the QR code to get started

CancerVision

What you'll receive

An extensive genetic testing report designed to cover your whole genome

Support from a genetic counselor to help you fully understand your test results and learn about treatment options

Clinical trial matching support and enrollment information based on your unique biomarkers

CancerVision

Mary Smith
Patient ID: H23/028662

Patient
Name: Mary Smith
Patient ID: H23/028662
Sex at birth: Female
Date of birth: Nov 20, 1987

Physician
Name: John Doe
Institution: Heritage Medical Center
Contact: +82-10-0000-0000
Address: 1600 Amphitheatre Parkway, Mountain View, CA 94043

Specimen
Specimen ID: C346399(9)
Specimen type: FFPE
Collected: Nov 20, 2023 14:10
Received: Nov 24, 2023
Normal sample: Matched blood
Normal obtained: Nov 20, 2023 20:20
Primary site: Breast, left
Sampling site: Breast, left
Diagnosis: Breast cancer, triple negative

Test Information
Test name: Target-enhanced whole genome analysis and interpretation
Quality: Satisfactory
Tumor Proportion: 48%

Sequencing mean depth
Tumor (WGS): 48.2x
Tumor (target): 523.2x
Normal (WGS): 25.2x

KEY FINDINGS SUMMARY - POTENTIALLY ACTIONABLE*

Therapeutics, in current diagnosis

Somatic alteration		
BRCA1 rearrangement	Talazoparib	Evidence B
	Olaparib	Evidence B
	Potential clinical trials: **Matched****	
Germline alteration		
RAD51C rearrangement	Potential clinical trials: **Matched****	

Therapeutics, In other indications

Somatic alteration	
BRCA1 rearrangement	Rucaparib
	Niraparib
	Olaparib
	Olaparib + Bevacizumab
	(+ 3 more options)
Genomic instability***	
HR deficiency	Rucaparib
	Niraparib

Cancer-related germline alteration

RAD51C rearrangement	Genetic counseling may be beneficial.

*The prescribing information for the FDA-approved therapeutic option may not include the associated alterations and it should be noted this information does not pertain to pediatric indications. Therapeutic options with evidence level A or B according to the ASCO/CAP guideline, are reported.
** See details in following pages.
*** While the TMB/MSI/HRD scores have been validated, this test is not FDA-approved as a companion diagnostic for therapeutic selection, including Anti-PD-1, and PARP inhibitor treatments.

Genomic instability

Tumor mutational burden	Low	High
Microsatellite instability	Stable	Instable
Homologous recombination	Proficient	Deficient

Somatic driver alteration

Point mutation

CDKN2A p.P81R	Missense variant
ATR p.W1471*	Stop-gain
PPARG p.A414P	Missense variant
ROS1 p.V1261L	Missense variant
ERCC2 p.I244F	Missense variant

INOCRAS Date Nov 23, 2023 Accession # 23-1385 CLIA # 05D2280195 Contact (866)665-2120 1 /9
Signed By Veena Singh, MD, FCAP, FACMG, Laboratory Director Address 6330 Nancy Ridge Drive, Suite 106, San Diego, CA 92121

Request an order for **CancerVision** testing today

at **inocras.com**

INOCRAS

INOCRAS.COM
6330 Nancy Ridge Drive, Suite 106
San Diego, CA 92121

Clinical Laboratory Improvement Amendments

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

HIPAA SEAL OF COMPLIANCE COMPLIANCY GROUP HIPAA VERIFIED